← VERTEX PHARMACEUTICALS INC / MA
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.7b |
$2.5b
+46.20%
|
$3.0b
+22.46%
|
$4.2b
+36.59%
|
$6.2b
+49.07%
|
$7.6b
+22.06%
|
$8.9b
+17.91%
|
$9.9b
+10.51%
|
$11.0b
+11.66%
|
$12.0b
+8.90%
|
$12.6b
+4.88%
|
|
| Cost of Revenue | $206.8m |
$272.7m
+31.85%
|
$409.5m
+50.19%
|
$547.8m
+33.75%
|
$736.3m
+34.42%
|
$904.2m
+22.80%
|
$1.1b
+19.48%
|
$1.3b
+16.84%
|
$1.5b
+21.26%
|
$1.7b
+7.89%
|
$1.8b
+6.75%
|
|
| Gross Profit (Calculated) | $1.5b |
$2.2b
+48.19%
|
$2.6b
+19.05%
|
$3.6b
+37.04%
|
$5.5b
+51.29%
|
$6.7b
+21.96%
|
$7.9b
+17.69%
|
$8.6b
+9.64%
|
$9.5b
+10.25%
|
$10.3b
+9.07%
|
— | |
| Interest Income (Expense), Net | — | — | — | — | — | ($61.5m) |
($54.8m)
+10.89%
|
($44.1m)
+19.53%
|
— | — | $489.7m | |
| Research and Development Expense | $1.0b | $1.3b | $1.4b | $1.8b | $1.8b | $3.1b | — | — | — | — | $4.0b | |
| Selling, General and Administrative Expense | $432.8m | $496.1m | $557.6m | $658.5m | $770.5m | $840.1m | $944.7m | $1.1b | $1.5b | $1.8b | $2.0b | |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | $1.7m | $20.2m | $20.2m | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | $9.9m |
$123.2m
+1140.37%
|
$635.1m
+415.36%
|
$1.2b
+88.55%
|
$2.9b
+138.51%
|
$2.8b
-2.60%
|
$4.3b
+54.83%
|
$3.8b
-11.04%
|
($232.9m)
-106.08%
|
$4.2b
+1891.88%
|
$4.8b
+14.46%
|
|
| Foreign Currency Transaction Gain (Loss), before Tax | $4.0m | $5.5m | ($1.1m) | ($5.2m) | ($16.1m) | ($13.9m) | ($15.1m) | ($24.6m) | ($27.3m) | ($13.7m) | — | |
| Other Nonoperating Income (Expense) | $4.1m | ($81.4m) | ($790k) | $192.2m | $296.4m | $4.9m | ($164.8m) | ($22.8m) | ($86.1m) | ($7.7m) | — | |
| Interest Expense (non-operating) | — | $69.3m | $72.5m | $58.5m | $58.2m | $61.5m | $54.8m | $44.1m | $30.6m | $13.3m | $17.0m | |
| Interest Income (Expense), Nonoperating, Net | ($81.4m) | ($57.5m) | ($34.1m) | — | — | — | — | — | — | — | $489.7m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($147.9m) | $330.3m | $812.1m | $1.3b | $2.9b | $2.0b | $3.3b | $3.1b | ($1.4b) | $2.8b | $5.3b | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $9.9m | $123.2m | $635.1m | $1.2b | $2.9b | $2.7b | $4.2b | $4.4b | $248.5m | $4.6b | $5.3b | |
| Current Income Tax Expense (Benefit) | ($191k) | $20.2m | $25.4m | $50.7m | $127.8m | $542.9m | $1.2b | $1.3b | $1.1b | $1.2b | $869.3m | |
| Income Tax Expense (Benefit) | $16.7m | ($107.3m) | ($1.5b) | $218.1m | $405.2m | $388.3m | $910.4m | $760.2m | $784.1m | $690.0m | $869.3m | |
| Net Income (Loss) Attributable to Parent | ($112.1m) |
$263.5m
+335.14%
|
$2.1b
+695.83%
|
$1.2b
-43.88%
|
$2.7b
+130.42%
|
$2.3b
-13.63%
|
$3.3b
+41.84%
|
$3.6b
+8.96%
|
($535.6m)
-114.80%
|
$4.0b
+838.09%
|
$4.4b
+11.43%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | — | $263.2m |
$2.1b
+696.53%
|
$1.2b
-43.87%
|
$2.7b
+130.42%
|
$9
-100.00%
|
$13
+42.68%
|
$14
+8.33%
|
($2)
-114.80%
|
$15
+843.27%
|
$4.4b
+28494178425.23%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | — | ($171.8m) | ($9.8m) | $0 | $0 | — | — | — | — | — | $4.4b | |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | $293k | $501k | $0 | $0 | — | — | — | — | — | — | |
| Earnings Per Share, Basic | ($0.46) | $1.06 | $8.24 | $4.58 | $10.44 | $9.09 | $12.97 | $14.05 | ($2.08) | $15.46 | $17.31 | |
| Earnings Per Share, Diluted | ($0.46) | $1.04 | $8.09 | $4.51 | $10.29 | $9.01 | $12.82 | $13.89 | ($2.08) | $15.32 | $17.17 | |
| Income (Loss) from Continuing Operations, Per Basic Share | ($0) | $1.06 | $8.24 | $4.58 | $10 | $9 | $13 | $14 | ($2) | $15 | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | ($0) | $1.06 | $8.24 | $4.58 | $10 | $9 | $13 | $14 | ($2) | $15 | — | |
| Weighted Average Number of Shares Outstanding, Basic | 244.7m | 248.9m | 254.3m | 256.7m | 259.8m | 257.7m | 256.1m | 257.7m | 257.9m | 255.7m | 254.2m | |
| Weighted Average Number of Shares Outstanding, Diluted | 244.7m | 253.2m | 259.2m | 260.7m | 263.4m | 259.9m | 259.1m | 260.5m | 257.9m | 258.0m | 256.2m | |
| Additional Financial Items | ||||||||||||
| Capitalized Computer Software, Amortization | — | — | — | — | — | — | — | $11.8m | $25.2m | $31.2m | — | |
| Costs and Expenses | $1.7b | $2.4b | $2.4b | $3.0b | $3.3b | $4.8b | $4.6b | $6.0b | $11.3b | $7.8b | — | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | $237.7m | $290.7m | $325.0m | $360.5m | $429.5m | — | $491.3m | $581.2m | $698.5m | $685.9m | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | ($112.1m) | $123.2m | $635.1m | $1.2b | $2.9b | $2.8b | $4.3b | $3.8b | $232.9m | $4.2b | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | ($84.0m) | $123.2m | $635.1m | $1.2b | $2.9b | $2.8b | $4.3b | $3.8b | $232.9m | $4.2b | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | $0 | $123.2m | $635.1m | $1.2b | $2.9b | $2.8b | $4.3b | $3.8b | $232.9m | $4.2b | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | $0 | $123.2m | $635.1m | $1.2b | $2.9b | $2.8b | $4.3b | $3.8b | $232.9m | $4.2b | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.